Genitourinary Division News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Genitourinary division. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Genitourinary Division Today - Breaking & Trending Today

Prostate Cancer Foundation partners with Digital Science Press / UroToday to launch NEW patient-centered website

/PRNewswire/ The Prostate Cancer Foundation (PCF), in collaboration with UroToday, is proud to announce the development and launch of a new educational. ....

Gina Carithers , Michael Salvadore Jr , Frank Verholen , Digital Science , Bayer Pharmaceuticals , Prostate Cancer Foundation , Digital Science Press , Prostate Cancer Patient , Prostate Cancer Patient Voices , Cancer Patient Voices , Vice President , Genitourinary Division , Medical Affairs , Publishing Amp Information Services , Multimedia Amp Internet , Health Care Amp Hospitals , Medical Pharmaceuticals , Computer Amp Electronics , African American , Quity Amp Inclusion , New Products Amp Services ,

Prostate Cancer Foundation partners with Digital Science Press / UroToday to launch NEW patient-centered website

/PRNewswire/ The Prostate Cancer Foundation (PCF), in collaboration with UroToday, is proud to announce the development and launch of a new educational. ....

Frank Verholen , Gina Carithers , Michael Salvadore Jr , Digital Science , Prostate Cancer Foundation , Bayer Pharmaceuticals , Digital Science Press , Prostate Cancer Patient , Prostate Cancer Patient Voices , Cancer Patient Voices , Vice President , Genitourinary Division , Medical Affairs ,

Pittsboro drug startup, National Cancer Institute team up to tackle metastatic prostate cancer

by Bryant Haskins, NCBiotech Writer February 24, 2021 .
RESEARCH TRIANGLE PARK – Pittsboro-based startup Propella Therapeutics is teaming up with the National Cancer Institute (NCI) to evaluate its new treatment for metastatic prostate cancer.
NCI and Propella have entered into a Cooperative Research and Development Agreement to run a multi-center clinical trial that will examine abiraterone decanoate. Propella holds a patent on this injectable prodrug of abiraterone. Prodrugs are inactive compounds that the body metabolizes into drugs.
Abiraterone is a powerful CYP 17 enzyme inhibitor that stops the production of testosterone and other male hormones – or androgens – that feed prostate cancer cells. Current treatments use abiraterone acetate, which if taken orally on a daily basis can make the body produce too much or too little abiraterone. And that can cause toxicity or be ineffective against cancer tumors. ....

United States , William Moore , Vizuri Health Sciences , Development Agreement , American Society Of Clinical Oncology , National Cancer Institute , Drug Administration , Genitourinary Division , Propella Therapeutics , Cooperative Research , American Society , Clinical Oncology , Propella President , Maryland Based Vizuri Health Sciences , ஒன்றுபட்டது மாநிலங்களில் , வில்லியம் மூர் , அமெரிக்கன் சமூகம் ஆஃப் மருத்துவ புற்றுநோயியல் , தேசிய புற்றுநோய் நிறுவனம் , ப்ரோப்பேல்லா சிகிச்சை , கூட்டுறவு ஆராய்ச்சி , அமெரிக்கன் சமூகம் , மருத்துவ புற்றுநோயியல் , ப்ரோப்பேல்லா ப்ரெஸிடெஂட் ,